Europe Board of Directors & Staff
Our Board of Directors and staff in Europe guide the Foundation's mission, set policies, monitor progress of NF research, and provide oversight and direction.
Our Board of Directors and staff in Europe guide the Foundation's mission, set policies, monitor progress of NF research, and provide oversight and direction.
Annette Bakker, the Children’s Tumor Foundation’s Chief Executive Officer, holds a PhD in cell biology from the University of Antwerp. Her past experience includes serving as Oncology Group Leader at Janssen Pharmaceutica, and postdoctoral fellowships at Yale University and La Salpetriere, Paris.
Before joining the Children’s Tumor Foundation, Dr. Bakker served as head of the Oncology R&D department for a biotech company in Siena, Tuscany. While there, she designed and created a neuro-oncology department from the ground up, and managed large oncology research initiatives both nationally (Italian networks) and internationally (European and Asian networks).
Dr. Bakker’s research has been internationally recognized by more than 30 peer-reviewed papers, patents, and awards, and she has extensive experience liaising and negotiating with biotechnology and pharmaceutical companies.
In her role at the Children’s Tumor Foundation, Annette and her team will continue to build a strong NF community, design and execute innovative business models to accelerate the path from basic discovery to clinical benefit for NF patients, develop partnerships with pharmaceutical and biotech industries, and attract new scientists and funders to the NF field.
Annette is originally from Belgium, and speaks four languages (English, French, Dutch, and Italian). She lives happily in Westchester, NY with her family.
Magda Chlebus is Executive Director Scientific & Regulatory Affairs at the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing the R&D-based pharmaceutical industry in Europe.
Magda and her team are in charge of following policy and legislative developments that influence the research and regulatory environments for the healthcare industry in Europe. This includes public private collaborations (inter alia the Innovative Medicines Initiative), enabling and sensitive technologies and the interface between new science and technology and regulation.
She joined EFPIA in 1995. Her experience covers public and government affairs mainly at EU level, on a range of legislative and non-legislative files in the area of research, development and access to medicines and enabling technologies.
Magda, a Polish national, holds a Master Degree in Applied Linguistics from the University of Warsaw.